The company made the announcement to pursue a US listing on July 31, 2018.  At that time the projected timeline for announcing topline results was still sometime in the 1Q 2019.  That would suggest that the initial plan was to list on the Nasdaq after the announcement of topline results since they didn’t have time to do it sooner.

The delay in achieving the target of 250 MACE has, perhaps involuntarily, provided the company with some flexibility in terms of when the Nasdaq listing could occur, assuming that Rothchilds has been able to put everything in place.  So, we could now expect the company will announce a Nasdaq listing prior to the announcement of topline results.  That said, I seem to recall someone mentioned a 3 month waiting period once the listing is confirmed which, if true, would still restrict any ability to trade on that exchange prior to or immediately after the announcement of topline results.

I think they will wait to see what the trial results are before making the Nasdaq announcement, if they are able to do that. After all, why do it if the result isn’t good?  But if topline results are positive then a Nasdaq announcement prior to the release of topline could be a very strong indication that the trial has met the desired endpoints.